SWOG clinical trial number
SWOG-8956

Study of Cisplatin and 5-FU Infusion for Treatment of Advanced and/or Recurrent Metastatic Carcinoma of the Urinary Bladder

Closed
Phase
Accrual
63%
Published
Abbreviated Title
Study of Cisplatin and 5-FU Infusion for Treatment of Advanced and/or Recurrent Metastatic Carcinoma of the Urinary Bladder
Activated
10/01/1990
Closed
06/15/1993

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

1997

Continuous infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: A Southwest Oncology Group trial.

JA Kish;MK Wolf;PF Schellhammer;MHA Hussain;AB Einstein;ED Crawford American Journal of Clinical Oncology 20(4):327-330

High dose cisplatin (C) and continuous infusion 5 fluorouracil (5FU CI) for the treatment of advanced/recurrent transitional cell cancer of the bladder (ARTCCB). Final report of a Southwest Oncology Group (SWOG) trial.

J Kish;M Wolf;P Schellhammer;M Hussain;A Einstein;E Crawford Proc Seventh International Congress on Anti-Cancer Treatment #254:

1993

Evaluation of cisplatin + 5 fluorouracil infusion for advanced/metastatic transitional cell carcinoma of the bladder. (AMTCCB). A Southwest Oncology Group study.

JA Kish;M Wolf;S Taylor;A Einstein;ED Crawford ASCO 34:203(#1214)

1992

Significant response rate to cisplatin + 5-fluorouracil in advanced/recurrent bladder cancer. A preliminary report. A Southwest Oncology Group study.

JA Kish;PF Schellhammer;M Wolf;AB Einstein Jr ASCO 11:219(#692)

Other Clinical Trials

SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase